Weekly newsletter

Index: State Ordered More of Richter-manufactured Covid Drug Remdesivir

Hungary Today 2020.11.12.

The state may have ordered more doses of Remdesivir, a Covid-19 drug manufactured domestically by Hungarian pharmaceutical company Gedeon Richter, enough to treat some 5,000 patients, according to Index’s information.  

In reference to unnamed sources, the portal now claims that Richter might have recently received a state order for doses enough to treat 5,000 patients, after in spring the government had already ordered doses enough to treat 3,000.

It made the news in mid-October that clinical testing of the virus inhibitor, originally developed by U.S. biopharmaceutical company Gilead Science against Ebola, could be kick-started in all of Hungary’s four medical universities.

According to Richter’s spokeswoman, the Hungarian government, which owns a 5.25% stake in Richter, approached the company during the first wave of the pandemic to find out whether Remdesivir could be manufactured locally. They have managed to solve the synthesis of the active substance within five months, she revealed.

Richter CEO: Remdesivir Production Started in "Record Time"
Richter CEO: Remdesivir Production Started in

Richter Gedeon Nyrt. CEO Gábor Orbán talked about the rapid development and production of the promising coronavirus medication and the relationship between the pandemic and the pharmaceutical industry in an interview given to Inforádió. To go from an existing recipe to producing remdesivir, Richter took a record five months instead of the more common twelve, […]Continue reading

The first patient, a woman aged 75 with diabetes, has since left the hospital. That time, Index, pointing to the government’s communication, assumed they hadn’t ordered more.

The drug is being given to Covid-19 patients hospitalized in serious condition. A positive test or obvious symptoms, the need for supplemental oxygen therapy, and the patient’s written consent qualifies eligibility and suitability for the therapy.

“Richter carries on its research and development activities on Remdesivir, which continues to enjoy the government’s support,” the company’s spokeswoman Zsuzsa Beke commented to Index.

Featured photo by Zsolt Czeglédi/MTI